Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qiangli Pipa Lu is a Traditional Chinese Medicine (TCM) oral liquid formulation primarily indicated for the treatment of cough associated with bronchitis. The formulation is characterized by its potent antitussive (cough-suppressant) and expectorant properties. It typically contains a combination of herbal extracts, including Eriobotryae Folium (loquat leaf), Papaveris Pericarpium (poppy husk), Cynanchi Stauntonii Rhizoma et Radix, Peucedani Radix, Mori Cortex, Platycodonis Radix, and Menthol. The inclusion of Papaveris Pericarpium provides a strong antitussive effect, likely mediated by opioid alkaloids acting on the central nervous system. The drug is developed and manufactured by companies such as Anqing Echo Biopharmaceutical (also known as Anqing Huabiao Biopharmaceutical) and is approved for marketing in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qiangli Pipa Lu.